Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Celgene Corp. (NasdaqNM:CELG)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
July 26Conference call: Celgene Earnings (Q2 2001)
Location
7 Powder Horn Drive
Warren, NJ 07059
Phone: (732) 271-1001
Fax: (732) 271-4184
Employees (last reported count): 316
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 10%
·Over the last 6 months:
 · 3 insider sells; 42.0K shares
  (0.6% of insider shares)
·Institutional: 65% (72% of float)
(399 institutions)
·Net Inst. Buying: 760.0K shares (+1.53%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Celgene Corporation is a biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small-molecule drugs for the treatment of cancer and inflammatory diseases, via gene regulation. The Company has developed and integrated a large set of proprietary target and drug discovery technologies to accelerate the application of genomics to the discovery of new classes of gene-regulating drugs. The Company's drug discovery and development programs are focused in several disease areas in which gene dysregulation plays a major role in the onset and progression of disease, including cancer and inflammatory diseases.
More from Market Guide: Expanded Business Description

Financial Summary
Celgene is a specialty company engaged in the development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases. For the six months ended 6/30/01, revenues rose 34% to $46.3 million. Net loss fell 82% to $2.3 million. Results reflect increased use of THALOMID by oncologists, the amortization of up-front payments on two agreements with Novartis and improved gross margins.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

John Jackson, 56
Chairman, CEO
$739K$26.5M
Sol Barer, Ph.D., 54
Pres, COO
517K12.9M
Robert Hugin, 46
Sr. VP and CFO
417K4.9M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CELGAs of 31-Aug-2001
Price and Volume
52-Week Low
on 26-Apr-2001
$14.40 
Recent Price$27.81 
52-Week High
on 5-Sep-2000
$76.00 
Beta0.89 
Daily Volume (3-month avg)1.56M
Daily Volume (10-day avg)1.34M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-62.8%
52-Week Change
relative to S&P500
-50.1%
Share-Related Items
Market Capitalization$2.10B
Shares Outstanding75.3M
Float67.8M
Dividends & Splits
Annual Dividendnone 
Last Split: 3 for 1 on 17-Apr-2000
Per-Share Data
Book Value (mrq)$4.01 
Earnings (ttm)-$0.11 
Earnings (mrq)-$0.03 
Sales (ttm)$1.30 
Cash (mrq)$3.96 
Valuation Ratios
Price/Book (mrq)6.94 
Price/EarningsN/A 
Price/Sales (ttm)21.44 
Income Statements
Sales (ttm)$96.4M
EBITDA (ttm)-$19.9M
Income available to common (ttm)-$7.25M
Profitability
Profit Margin (ttm)-7.5%
Operating Margin (ttm)-30.1%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-2.15%
Return on Equity (ttm)-2.49%
Financial Strength
Current Ratio (mrq)15.75 
Debt/Equity (mrq)0.04 
Total Cash (mrq)$298.4M
Short Interest
As of 8-Aug-2001
Shares Short5.09M
Percent of Float7.5%
Shares Short
(Prior Month)
5.68M
Short Ratio5.96 
Daily Volume855.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.